Form 4 for RNAC Cartesian Therapeutics, Inc.
Accepted 2022-12-05 00:00:00 ET · period of report 2022-12-01 · accession 0001453687-22-000145 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-12-05 | 2022-12-01 | RNAC | Brunn Carsten | Pres, CEO, Dir | M - OptEx | $0.00 | +10.9K | 548.8K | +2% | $0 |
| D | 2022-12-05 | 2022-12-01 | RNAC | Brunn Carsten | Pres, CEO, Dir | M - OptEx | $0.00 | -10.9K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-01 | M | A | 10,938 | $0.00 | 548,805 | D | — | — | |
| 2 | Derivative | Restricted Stock Units | 2022-12-01 | M | D | 10,938 | $0.00 | 0 | D | — · — to — | 10,938 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock. (F2) This restricted stock unit award is fully vested and has no expiration date |